ArticleJournal of cardiovascular electrophysiology2025
Non-Endocardial Radiofrequency Ablation of Premature Ventricular Complexes (NERA-PVC): Safety, Efficacy and Outcome.
Article in Journal of cardiovascular electrophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intramural left ventricular posterior superior process premature ventricular complex ablation with intracardiac echocardiography.Indian pacing and electrophysiology journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundRadiofrequency (RF) ablation of premature ventricular complexes (PVCs) is a well-established treatment for patients high PVCs burden, even when arising from epicardial/intramural localization. Consistent data about safety of using high power RF is lacking in the literature in these regions.
aimThe aim of this study is to investigate the safety of different RF power settings, efficacy and outcome of non-endocardial PVCs ablation.
methodsConsecutive patients who underwent PVC ablation were included (2017-2023). We defined "Non-Endocardial Radiofrequency Ablation"(NERA) a procedure in which at least one ablation site has been identified into the CVS, aortic cusps, inter-leaflet region or pulmonary cusps.
resultsTotal number of NERA sites was 64 in 56 procedures. In 63% of the procedures, high power (≥ 40 W) and in 60% long duration (≥ 60 s) RF was delivered in at least one site (median power: 40 W(30-40), median duration of single RF 54 s(45-91). In 21% of the procedures, a combination of both high power and long duration RF applications was performed. Overall procedural success was achieved in 46 procedures 82%), complete in 39 (70%), partial in 7 (12%). Only one severe complication (pericardial bleeding) was observed. Multisite ablation was associated with procedural failure. During follow-up, median PVC burden was 0.5%(0.5-9.5), with a median reduction of 97%. Multisite ablation and coronary venous system RF were predictors of recurrence (HR 3.6; p = 0.03) and HR 3.85; p = 0.02).
conclusionAblation from non-endocardial sites is a safe and effective procedure, even using high power and/or long duration RF with clear benefit in terms of PVC burden reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.